GLRA
XLRN

Gerald L. Ray & Associates’s Acceleron Pharma XLRN Stock Holding History

Gerald L. Ray & Associates’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$321K Sell
8,600
-1,000
-10% -$34.7K 0.04% 270
2017
Q2 		$292K Buy
+9,600
New +$278K 0.04% 273

Other funds holding XLRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Gerald L. Ray & Associates's XLRN Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Acceleron Pharma (XLRN) stake by 10% in Q3 2017, selling an estimated $34.7K and leaving 8,600 shares worth $321K. The position accounts for 0.04% of the portfolio, ranked #270.

Gerald L. Ray & Associates first reported a position in XLRN in Q2 2017 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

  • Gerald L. Ray & Associates held 8,600 shares of Acceleron Pharma worth $321K as of Q3 2017.
  • Gerald L. Ray & Associates sold 1,000 Acceleron Pharma shares in Q3 2017, an estimated $34.7K.
  • Acceleron Pharma made up 0.04% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #270 holding.
  • Gerald L. Ray & Associates first reported a position in Acceleron Pharma in Q2 2017 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.